Smoking Topography Study 2018
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Apr 6, 2018
Trial Information
Current as of June 08, 2025
Completed
Keywords
ClinConnect Summary
In 2005, the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) was established with the aim for a regulatory strategy as a response to the globalization of the tobacco epidemic. One of their non-price measures to reduce the demand for tobacco includes article 9: Regulation of the contents of tobacco products . Cigarette product regulation is currently based on tar, nicotine and carbon monoxide (TNCO) levels in cigarette smoke, which are indicated on the package. This is not sufficient, since cigarette smoke includes more than 7000 chemicals. There are aldehydes, V...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male
- • 25-35 years old (birth year 1982 - 1992)
- • Caucasian
- • Smoking Marlboro as usual brand for at least 3 years
- • Used to smoke between 13 and 25 cigarettes a day (around a package/day)
- Exclusion Criteria:
- • Heavy smoker (minimum of 25 cigarettes/day)
- • Smokes more than 1 brand on a regular base.
- • Amount of cigarettes per day varies ±10, between days
- • Daily medication use
- • Experienced adverse effects due to smoking
- • Suffering chronic illness
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, , Netherlands
Patients applied
Trial Officials
Agnes Boots, PhD
Principal Investigator
Maastricht University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials